Clinical and pathological factors and outcome of central nervous system metastasis in breast cancer

Frontiers in Oncology

Oncology

Christian Kurzeder¹  Elena-Diana Chiru²  Andreas Schötzau³  Vérène Dougoud-Chauvin⁴  Alfred Zippelius⁵  Dimitri Dettwiler⁵  Eveline Daetwyler⁵  Marcus Vetter⁶  Markus W. Gross⁷ 

[1]Breast Center, University Hospital Basel, Basel, Switzerland

[2]Cancer Center, Medical University Clinics, Kantonsspital Baselland, Liestal, Switzerland

[3]Department of Gynecologic Oncology, University Hospital Basel, Basel, Switzerland

[4]Department of Medical Oncology, Kantonsspital HFR Freiburg, Fribourg, Switzerland

[5]Department of Medical Oncology, University Hospital Basel, Basel, Switzerland

[6]Department of Medical Oncology, University Hospital Basel, Basel, Switzerland

[7]Breast Center, University Hospital Basel, Basel, Switzerland

[8]Cancer Center Baselland, Medical University Clinic Baselland, Liestal, Switzerland

[9]Cancer Center, Medical University Clinics, Kantonsspital Baselland, Liestal, Switzerland

[10]Department of Radiooncology, University Hospital Basel, Basel, Switzerland

关键词: metastatic breast cancer;    brain metastasis;    meningeal carcinomatosis;    older patients with breast cancer;    long-term survivors with breast cancer and brain metastases;   

DOI  :  10.3389/fonc.2023.1247402

 received in 2023-06-26, accepted in 2023-09-04,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundIn Switzerland, approximately 6000 new breast cancer cases and 1300 deaths are reported annually. Brain metastasis from breast cancer (BMBC) has a major effect on prognosis. This study aimed to identify prognostic factors for overall survival (OS) in a cohort of Swiss patients with BMBC. This study evaluated the prognosis on older BMBC, which has not been completely addressed in the literature.MethodsWe performed a retrospective chart review analysis with the primary endpoint of OS after a diagnosis of BMBC. The study population was divided into 2 groups based on an OS cut-off value of 12 months after diagnosis. Univariate and multivariate analyses of several risk factors, including age, were performed. To evaluate differences in OS according to age, we performed a secondary analysis to examine the prognostic value of clinical symptoms, metastatic pattern, and lymph node involvement in an older (≥65 years) vs. younger (<65 years) cohort.ResultsFrom 1989 to 2019, 55 patients were identified as having BMBC, among whom 47 patients were confirmed to be dead. The median patient age was 58 years (range 25–83 years). Comorbidities were present in 45 (81.8%) patients. The median survival in the OS <12 and OS ≥12 months groups was 4.3 and 30.7 months, respectively (p<0.001). Multivariate analysis revealed no significant differences in terms of comorbidities, medication use, M-stage, and symptomatology between the 2 groups. Additionally, there was no significant difference in OS in the 2 subgroups of patients aged <65 and ≥65 years.DiscussionWe concluded that age should not be a decisive factor in therapy planning for advanced breast cancer patients with BMBC.

【 授权许可】

Unknown   
Copyright © 2023 Dettwiler, Chiru, Daetwyler, Dougoud-Chauvin, Gross, Kurzeder, Zippelius, Schötzau and Vetter